Presence of a TP53 mutation or strong nuclear expression of p53 in > 10% of tumor cells is a desirable finding as well as a methylation profile of “astrocytoma, IDH-mutant” and an astrocytic differentiation by morphology. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).